Investor Presentaiton
6
Danaher 2024+: A Focused Science & Technology Leader
BIOTECHNOLOGY: ~$8.8B 2022 REVENUE
LIFE SCIENCES: ~$7.0B 2022 REVENUE
DIAGNOSTICS: ~$10.8B 2022 REVENUE
BIOPROCESSING
HSD
LONG-TERM
GROWTH RATE*
RESEARCH,
LAB & MEDICAL
DD+*
GENOMICS
HSD
LONG-TERM
GROWTH RATE*
MSD+*
LS INSTRUMENTS
HSD*
PATHOLOGY &
ACUTE / POC
MSD*
CLINICAL
HSD
LONG-TERM
GROWTH RATE*
LDD*
MOLECULAR
cytiva
PALL
Life Sciences
COULTER
Life Sciences
MICROSYSTEMS
XXIDT
BECKMAN Leica SCIEX
PALL
Industrial
aldevron
INTEGRATED DNA KORNGLOGES
BECKMAN
COULTER
Leica
BIOSYSTEMS
Cepheid.
RADIOMETER R
*Anticipated long-term core revenue growth rate.
Pie charts reflect FY 2022 revenue by product line.
Outstanding businesses focused on impacting human health
DANAHERView entire presentation